Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …

The treatment of acute ischemic stroke continues to advance. The mainstay of treatment
remains intravenous thrombolysis with alteplase. Recent studies demonstrated that later …

Background Tenecteplase is an effective thrombolytic agent for eligible patients with stroke
who are treated within 4.5 hours after the onset of stroke. However, data regarding the …

Background There is increasing interest in replacing alteplase with tenecteplase as the
preferred thrombolytic treatment for patients with acute ischaemic stroke. We aimed to …

Within the last year, four randomised-controlled clinical trials (RCTs) have been published
comparing intravenous thrombolysis (IVT) with tenecteplase and alteplase in acute …

Abstract Background and Aim: Despite progress made over the last 30 years, stroke is still a
leading cause of disability and mortality; likewise, its burden is expected to increase over the …

Background Individuals with minor ischaemic stroke and intracranial occlusion are at
increased risk of poor outcomes. Intravenous thrombolysis with tenecteplase might improve …

Importance Tenecteplase is being evaluated as an alternative thrombolytic agent for the
treatment of acute ischemic stroke (AIS) within ongoing randomized clinical trials (RCTs). In …

Although intravenous thrombolysis with alteplase remains the primary treatment for acute
ischemic stroke, tenecteplase has shown potential advantages over alteplase. Animal …

Background and Purpose: Due to practical advantages, increasing trial safety data, recent
Australian Guideline endorsement and local population needs we switched to tenecteplase …